Fiasp - a new, ultra-fast acting mealtime insulin
Canada first country to launch Fiasp.
Novo Nordisk has announced that Fiasp, a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.
Fiasp is insulin aspart in an innovative formulation that more closely matches the natural physiological insulin response of a person without diabetes after a meal, compared with NovoRapid (conventional insulin aspart). Fiasp also has the option of a flexible dosing regimen (up to 20 minutes after starting a meal), without compromising overall glycaemic control, when compared to NovoRapid dosed at mealtime.
"The launch of Fiasp in Canada represents the first new mealtime insulin in 10 years. We hope to make this innovation available to as many people with diabetes as possible worldwide," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The goal of any insulin treatment is to match the natural physiological insulin production we see in people without diabetes, both in speed and glycaemic control. Fiasp has narrowed the existing gap, getting us closer to that goal."
Fiasp is absorbed faster than NovoRapid, appearing twice as fast in the bloodstream after injection, which leads to improved glycaemic control after a meal. In clinical trials, Fiasp demonstrated improved overall glycaemic control in type 1 diabetes2 and comparable overall glycaemic control in type 2 diabetes, versus NovoRapid. Results also showed improved mealtime glucose control in type 1 and type 2 diabetes. This was achieved without a significant difference in the overall rate of severe or confirmed hypoglycaemia, compared with NovoRapid.
Clinical trial results showed that the faster absorption of Fiasp, compared to NovoRapid®, was even more pronounced in those using a continuous subcutaneous insulin infusion (CSII) system (insulin pump therapy). In addition, when compared with NovoRapid in a CSII setting in people with type 1 diabetes, Fiasp showed no difference in pump compatibility as assessed by microscopically confirmed infusion-set occlusions, and the treatments were equally effective in controlling glucose levels, compared to NovoRapid.
“People living with diabetes often struggle to control blood glucose around mealtimes, which can be extremely challenging and result in debilitating diabetes-related complications,” said Dr Rémi Rabasa-Lhoret, endocrinologist at the Institut de Recherches Cliniques de Montréal and onset 1 investigator. “With the approval of a faster-acting insulin, one that is closer to the natural physiological insulin response of a person without diabetes, we can further support people in managing their blood glucose levels around meals, which may help prevent hyperglycaemia, for instance, a condition that can cause serious complications for people living with diabetes.”
Following the first country launch in Canada, Fiasp will also be available in a number of European markets in the coming months.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance